Status:
COMPLETED
Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
Lead Sponsor:
Rehab Werida
Conditions:
Inflammatory Bowel Diseases
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This study aims to assess trough, TREM-1 levels and efficacy of IFX and ADA in IBD patients.
Detailed Description
1\. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour University 2. All participants agree to take part in this clinical study, will agree to provide an inform...
Eligibility Criteria
Inclusion
- Adult patients between 18 years and 80 years.
- Patients having moderate to severe IBD according to European Crohn's and colitis organization (ECCO) guidelines.
- IBD patients receiving either IFX or ADA.
Exclusion
- Patients missed one-year follow-up or with missed data.
- Patients having mild IBD according to ECCO guidelines.
- Patients having any of the Contraindications to the biological Therapy e.g.: latent TB, viral or fungal or bacterial infection.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2023
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT05291039
Start Date
January 1 2022
End Date
April 1 2023
Last Update
March 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tropical Medicine department, Ain Shams University Hospitals.
Cairo, Egypt, 31527